Alkermes PLC (ALKS) SVP James M. Frates Sells 20,932 Shares of Stock
Alkermes PLC (NASDAQ:ALKS) SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total transaction of $995,944.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Alkermes PLC (NASDAQ:ALKS) traded down $0.20 during midday trading on Friday, hitting $47.85. 1,285,195 shares of the company traded hands, compared to its average volume of 831,124. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 12 month low of $46.80 and a 12 month high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 20.6% on a year-over-year basis. analysts anticipate that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.
A number of research firms recently issued reports on ALKS. Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Barclays PLC downgraded shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $66.00 to $50.00 in a report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Friday, October 27th. Finally, UBS AG set a $54.00 price objective on shares of Alkermes PLC and gave the stock a “hold” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $63.55.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC increased its position in Alkermes PLC by 11.8% during the 1st quarter. Teachers Advisors LLC now owns 155,311 shares of the company’s stock valued at $9,086,000 after purchasing an additional 16,354 shares during the period. PNC Financial Services Group Inc. increased its position in Alkermes PLC by 0.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock valued at $415,000 after purchasing an additional 42 shares during the period. Dimensional Fund Advisors LP increased its position in Alkermes PLC by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock valued at $11,381,000 after purchasing an additional 2,891 shares during the period. Renaissance Technologies LLC purchased a new position in Alkermes PLC during the 1st quarter valued at $7,306,000. Finally, Capstone Asset Management Co. increased its position in Alkermes PLC by 2.6% during the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after purchasing an additional 170 shares during the period. 98.19% of the stock is currently owned by institutional investors.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.